AU2020277489A1 - Anti-ROR1/anti-CD3 bispecific binding molecules - Google Patents

Anti-ROR1/anti-CD3 bispecific binding molecules Download PDF

Info

Publication number
AU2020277489A1
AU2020277489A1 AU2020277489A AU2020277489A AU2020277489A1 AU 2020277489 A1 AU2020277489 A1 AU 2020277489A1 AU 2020277489 A AU2020277489 A AU 2020277489A AU 2020277489 A AU2020277489 A AU 2020277489A AU 2020277489 A1 AU2020277489 A1 AU 2020277489A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
nos
antigen
binding domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020277489A
Other languages
English (en)
Inventor
Katti JESSEN
Mira KO
Brian Lannutti
Thanh-Trang VO
J. Monty WATKINS
Jeffry D. Watkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Velosbio Inc
Original Assignee
Velosbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Velosbio Inc filed Critical Velosbio Inc
Publication of AU2020277489A1 publication Critical patent/AU2020277489A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020277489A 2019-05-23 2020-05-22 Anti-ROR1/anti-CD3 bispecific binding molecules Pending AU2020277489A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852039P 2019-05-23 2019-05-23
US62/852,039 2019-05-23
PCT/US2020/034281 WO2020237173A1 (en) 2019-05-23 2020-05-22 Anti-ror1/anti-cd3 bispecific binding molecules

Publications (1)

Publication Number Publication Date
AU2020277489A1 true AU2020277489A1 (en) 2021-11-25

Family

ID=71078637

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020277489A Pending AU2020277489A1 (en) 2019-05-23 2020-05-22 Anti-ROR1/anti-CD3 bispecific binding molecules

Country Status (11)

Country Link
US (1) US20220227866A1 (https=)
EP (1) EP3972999A1 (https=)
JP (1) JP7611171B2 (https=)
KR (1) KR20220012313A (https=)
CN (1) CN113874399B (https=)
AU (1) AU2020277489A1 (https=)
BR (1) BR112021023026A2 (https=)
CA (1) CA3139111A1 (https=)
MX (1) MX2021014193A (https=)
TW (1) TWI899079B (https=)
WO (1) WO2020237173A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504620A (ja) * 2019-12-06 2023-02-06 オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 抗ｏｘＭＩＦ／抗ＣＤ３二重特異性抗体構築物
CA3166286A1 (en) 2020-02-07 2021-08-12 Jeffry D. Watkins Anti-ror1 antibodies and compositions
MX2023009022A (es) * 2021-02-02 2023-10-23 Numab Therapeutics AG Anticuerpos multiespecificos con especificidad para ror1 y cd3.
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
WO2023000791A1 (en) * 2021-07-23 2023-01-26 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against ror1 and uses thereof
WO2023056556A1 (en) * 2021-10-07 2023-04-13 National Research Council Of Canada Anti-cd3 monoclonal antibodies and therapeutic constructs
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3803790B2 (ja) * 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
PL3489261T3 (pl) * 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
EP2981281B1 (en) 2013-04-03 2020-07-15 IBC Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
CN110627907B (zh) * 2013-11-04 2024-03-29 艾科诺斯科技股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
US10519248B2 (en) * 2014-07-25 2019-12-31 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3091032A1 (en) 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3
WO2017125897A1 (en) * 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
KR20180100238A (ko) * 2016-01-22 2018-09-07 얀센 바이오테크 인코포레이티드 항-ror1 항체, ror1 × cd3 이중특이성 항체, 및 이를 사용하는 방법
TW201730212A (zh) 2016-02-17 2017-09-01 宏觀基因股份有限公司 Ｒｏｒ１－結合分子及其使用方法
WO2018140831A2 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
MX2019015057A (es) * 2017-06-23 2020-08-03 Velosbio Inc Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1).
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
WO2019084060A1 (en) * 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
CA3166286A1 (en) * 2020-02-07 2021-08-12 Jeffry D. Watkins Anti-ror1 antibodies and compositions

Also Published As

Publication number Publication date
KR20220012313A (ko) 2022-02-03
US20220227866A1 (en) 2022-07-21
EP3972999A1 (en) 2022-03-30
BR112021023026A2 (pt) 2022-01-04
JP7611171B2 (ja) 2025-01-09
MX2021014193A (es) 2022-01-06
CN113874399A (zh) 2021-12-31
CA3139111A1 (en) 2020-11-26
TW202110887A (zh) 2021-03-16
CN113874399B (zh) 2025-07-11
WO2020237173A1 (en) 2020-11-26
TWI899079B (zh) 2025-10-01
JP2022533418A (ja) 2022-07-22

Similar Documents

Publication Publication Date Title
JP7611171B2 (ja) 抗ｒｏｒ１／抗ｃｄ３二重特異性結合分子
JP7551693B2 (ja) ＮＫｐ４６結合タンパク質の可変領域
US12497454B2 (en) Anti-ROR1 antibodies and compositions
BR112021009325A2 (pt) Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica
KR20180095086A (ko) 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
EP3313881A1 (en) Multispecific nk engager proteins
KR20240145470A (ko) 항-tigit 항체 및 항-pd-1/항-vegfa 이중특이적 항체를 포함하는 약제학적 조성물 및 용도
JP2024504471A (ja) Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
AU2021214622B2 (en) Means and method for modulating immune cell engaging effects.
JP2024515396A (ja) 抗ｃｄ４７モノクローナル抗体及びその使用
KR20240016991A (ko) 항-nkg2a 항체 및 조성물
CA3256036A1 (en) Anti-PVRIG antibodies, pharmaceutical composition and associated uses
KR20260018083A (ko) 항-fgfr2/pd-1 이중특이항체
JP7753401B2 (ja) ヒト化抗ｃｌｅｃ－１ａ抗体及びその抗原結合断片及びそのミメティック
RU2831608C2 (ru) Анти-ror1/анти-cd3 биспецифические связывающие молекулы
AU2026202063A1 (en) Means and method for modulating immune cell engaging effects.
TW202448504A (zh) Btn3a活化抗體及免疫檢查點抑制劑之組合